Target intelligence / Profile preview

Gastric mucosal layer glycoproteins

Molecular classification
Glycoprotein, Secreted mucin, Other
01

Overview

The gastric mucosal layer glycoproteins consist mainly of secreted, high-molecular-weight mucins, with Mucin-5AC and Mucin-6 being the principal components in the stomach. These gel-forming, O-glycosylated proteins are secreted by epithelial cells to create a thick, viscoelastic barrier atop the gastric epithelium[3][6][5]. This layer protects the stomach lining from corrosive acid, digestive enzymes, pathogens, and mechanical friction caused by food. The structure and glycosylation pattern of these mucins are dynamic and can be altered in diseases like gastritis, gastric ulcer, Helicobacter pylori infection, and gastric cancer[3][6][4]. Although drugs may influence mucin secretion or the integrity of the mucus barrier, these glycoproteins themselves are not typically direct molecular drug targets. This entity is not a classical drug target but refers to a physiological barrier composed of mucin family glycoproteins, most prominently Mucin-5AC and Mucin-6[3][6][5].

Other names
Gastric mucinsGastric mucus glycoproteinsMucin-6 (MUC6)MUC5ACMUC6
02

Mechanism of action

Not applicable as a direct target. Drugs may increase mucin secretion or stabilize mucus gel indirectly[5]

03

Biological functions

Formation of the gastric mucus gel barrierProtection of gastric epithelium from acid and proteolytic enzymesLubrication of stomach contents[5][6]
04

Disease associations

Gastric ulcer (loss or alteration of mucins)[6]Helicobacter pylori infection (bacterial colonization depends on mucin glycosylation)[3]Gastric cancer (altered mucin expression/glycosylation)[3]Inflammation (gastritis)[3]
05

Safety considerations

Loss of protective mucins increases risk of gastric injury, ulceration, and infection (but not a concern for targeting, since not a direct target)[5]
06

Interacting drugs

prostaglandin analogs

1 more in the full profile.

07

Biomarkers

Altered expression/glycosylation of MUC5AC or MUC6 is used as a biomarker in some gastric diseases, including cancer and Helicobacter pylori infection[3]

Beyond the preview

Go deeper on Gastric mucosal layer glycoproteins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastric mucosal layer glycoproteins.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call